Literature DB >> 27053543

Acute fibrinous and organising pneumonia: a rare histopathological variant of chemotherapy-induced lung injury.

Arjun Gupta1, Shiraj Sen2, Harris Naina1.   

Abstract

Bleomycin-induced lung injury is the most common chemotherapy-associated lung disease, and is linked with several histopathological patterns. Acute fibrinous and organising pneumonia (AFOP) is a relatively new and rare histological pattern of diffuse lung injury. We report the first known case of bleomycin-induced AFOP. A 36-year-old man with metastatic testicular cancer received three cycles of bleomycin, etoposide and cisplatin, before being transitioned to paclitaxel, ifosfamide and cisplatin. He subsequently presented with exertional dyspnoea, cough and pleuritic chest pain. CT of the chest demonstrated bilateral ground glass opacities with peribronchovascular distribution and pulmonary function tests demonstrated a restrictive pattern of lung disease with impaired diffusion. Transbronchial biopsy revealed intra-alveolar fibrin deposits with organising pneumonia, consisting of intraluminal loose connective tissue consistent with AFOP. The patient received high-dose corticosteroids with symptomatic and radiographic improvement. AFOP should be recognised as a histopathological variant of bleomycin-induced lung injury. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27053543      PMCID: PMC4840647          DOI: 10.1136/bcr-2016-214721

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations.

Authors:  C Isabela S Silva; Nestor L Müller
Journal:  Semin Ultrasound CT MR       Date:  2006-04       Impact factor: 1.875

2.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.

Authors:  J M O'Sullivan; R A Huddart; A R Norman; J Nicholls; D P Dearnaley; A Horwich
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

Review 3.  Delayed onset bleomycin-induced pneumonitis.

Authors:  I Uzel; M Ozguroglu; B Uzel; K Kaynak; O Demirhan; C Akman; F Oz; M Yaman
Journal:  Urology       Date:  2005-07       Impact factor: 2.649

4.  Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency.

Authors:  B F McLeod; H J Lawrence; D W Smith; P J Vogt; D R Gandara
Journal:  Cancer       Date:  1987-12-01       Impact factor: 6.860

Review 5.  Bleomycins: towards better therapeutics.

Authors:  Jingyang Chen; JoAnne Stubbe
Journal:  Nat Rev Cancer       Date:  2005-02       Impact factor: 60.716

6.  Increased pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations.

Authors:  M Rabinowits; L Souhami; R A Gil; C A Andrade; H C Paiva
Journal:  Am J Clin Oncol       Date:  1990-04       Impact factor: 2.339

Review 7.  Bleomycin-induced pulmonary toxicity.

Authors:  K Jules-Elysee; D A White
Journal:  Clin Chest Med       Date:  1990-03       Impact factor: 2.878

8.  Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage.

Authors:  Mary Beth Beasley; Teri J Franks; Jeffrey R Galvin; Bernadette Gochuico; William D Travis
Journal:  Arch Pathol Lab Med       Date:  2002-09       Impact factor: 5.534

9.  Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy.

Authors:  M L Samuels; D E Johnson; P Y Holoye; V J Lanzotti
Journal:  JAMA       Date:  1976-03-15       Impact factor: 56.272

10.  Bleomycin pulmonary toxicity: its relationship to renal dysfunction.

Authors:  A G Dalgleish; R L Woods; J A Levi
Journal:  Med Pediatr Oncol       Date:  1984
  10 in total
  1 in total

1.  Short-Course of Methylprednisolone Improves Respiratory Functional Parameters After 120 Days in Hospitalized COVID-19 Patients (Metcovid Trial): A Randomized Clinical Trial.

Authors:  Camila Miriam Suemi Sato Barros; Raissa Soares Freire; Elisângela Frota; Anna Gabriela Rezende Santos; Maria Eduarda Leão Farias; Maria Gabriela Almeida Rodrigues; Bernardo Maia Silva; Christiane Maria Prado Jeronimo; Rebeca Linhares Abreu Netto; Mayla Gabriela Silva Borba; Djane Baía-da-Silva; José Diego Brito-Sousa; Mariana Simão Xavier; Marcia Almeida Araújo-Alexandre; Vanderson Souza Sampaio; Gisely Cardoso Melo; Guilherme Tinoco Arêas; Ludhmila Abrahão Hajjar; Wuelton Marcelo Monteiro; Felipe Gomes Naveca; Fábio Trindade Maranhão Costa; Fernando Fonseca Almeida Val; Marcus Vinícius Guimarães Lacerda
Journal:  Front Med (Lausanne)       Date:  2021-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.